Clinical trials: Allogeneic Transplantation
Degenerative Disc Disease
Intervertebral Disc Augmentation With Minimally Invasive Surgical Procedure
The primary purpose of the study is to establish the degree and duration of pain relief following minimally invasive surgery for a painful degenerative disc.
- Trial name
- NCT01442922
- Testing
- completion of the (VAS) for level of back pain, completion of the (OLBPQ) for assessment of function
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Florida
Untreated Myelodysplastic Syndrome
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
This phase I/II open-label, dose-finding, multi-center study will assess safety and primary efficacy of Onureg and Venetoclax combination, to define the optimal biological dose and optimal treatment duration of Onureg to be used…
- Trial name
- NCT05782127
- Testing
- Onureg + Venetoclax
- Where
- 25 sites in France
- Volunteers
- 36 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Malignant Hemopathy
Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells
Chemotherapy or targeted therapy are usually used to treat hematological pathologies. Despite of medical improvement, some of these pathologies present drug resistances, or high risk of relapse.
- Trial name
- MENTALO (NCT04517656)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Renal Allograft Recipients
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
The purpose of this study is to evaluate the benefits and risks of conversion of existing adolescent kidney allograft recipients aged 12 to less than 18 years of age to a belatacept-based immunosuppressive regimen as compared to…
- Trial name
- NCT04877288
- Testing
- Belatacept, Tacrolimus, Cyclosporine A
- Where
- 38 sites in United States, Argentina and 8 more
- Volunteers
- 102 people
- Sponsor
- Bristol-Myers Squibb
Disorder Related to Cardiac Transplantation
Assessment of Cardiac Allograft Vasculopathy by Optical Coherence Tomography
Cardiac allograft vasculopathy (CAV) is characterized by marked intimal proliferation and concentric vascular thickening and fibrosis. CAV remains the leading cause of late morbidity and mortality in heart transplant recipients.
- Trial name
- EARLY-OCT (NCT02503566)
- Testing
- Optical coherence tomography
- Where
- 2 sites in Czechia
- Volunteers
- 150 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Acute Myeloid Leukemia
A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
The researchers are doing this study to find out if an allogeneic hematopoietic stem cell transplant (HSCT) or maintenance therapy with azacitidine and venetoclax is more effective at keeping AML from coming back (relapsing).
- Trial name
- NCT06903702
- Testing
- Azacitidine (AZA), Venetoclax, Allogeneic hematopoietic stem cell transplantation
- Sponsor
- Memorial Sloan Kettering Cancer Center
Kidney Transplantation
Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
This is a multicentre study examining the use of Advagraf-minimization strategy and/or the use of an inhibitor of the renin-angiotensin system in reducing chronic rejection in renal allografts.
- Trial name
- NCT00933231
- Testing
- tacrolimus, Simulect, Cellcept
- Where
- 13 sites in Canada
- Volunteers
- 281 people
- Sponsor
- Astellas Pharma Inc
T-cell Lymphoma, Leukaemia
High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
Patients are recruited at diagnosis or at relapse of ATLL-HR in French Caribbean islands and Guyana. They all receive Zidovudine and Pegylated Interferon (ZPI).
- Trial name
- ATLL-HR-01 (NCT01941680)
- Where
- 2 sites in Guadeloupe, Martinique
- Volunteers
- 20 people
- Sponsor
- University Hospital Center of Martinique
Degenerative Disc Disease, Spinal Stenosis Lumbar
Prospective Study of ProteiOS in Lumbar Interbody Fusion (TLIF)
This is a prospective, multicenter, randomized, controlled study evaluating Influx™ ProteiOS®, an allograft-derived growth factor product, in transforaminal lumbar interbody fusion (TLIF).
- Conditions
- Degenerative Disc Disease, Spinal Stenosis Lumbar, Lumbar Spine Fusion, Spondylolisthesis
- Trial name
- NCT07775729
- Testing
- Allograft-derived growth factor (ProteiOS®), Standard of Care (SOC)
- Volunteers
- 280 people
- Sponsor
- Isto Biologics
Hematological Neoplasms, Hematopoietic Stem Cell Transplantation
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases
- Trial name
- NCT00582894
- Testing
- Busulfex, Fludarabine, ALemtuzumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Oklahoma
Vaccination, Hematopoietic Stem Cells
Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients
Hematopoietic stem cell transplantation (HSCT) is a cellular therapy aiming at curing some hematological diseases. Upon transplantation, recipients experience a phase of profound immune suppression with loss of protective…
- Trial name
- VaccHemInf (NCT03659773)
- Testing
- immune biomarkers to evaluate vaccine response in HSCT recipients
- Where
- 2 sites in France
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Kidney Cancer
Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, before a donor peripheral blood stem cell transplant helps stop the growth of tumor cells.
- Trial name
- NCT00003553
- Testing
- HLA Matched Peripheral BLood Stem Cells
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Kidney Transplantation
BIOMARGIN European, Ambispective Cohort of Adult and Paediatric Renal Transplant Patients
Biomargin is a European research program aimed at evaluating the diagnostic performance of biomarkers with respect to renal graft injuries, as well as their prognostic performance with respect to 3-year and 5-year graft outcomes.
- Trial name
- BECS (NCT02832661)
- Where
- 6 sites in Belgium, France and 1 more
- Volunteers
- 500 people
- Sponsor
- University Hospital, Limoges
Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia
Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
Traditional salvage chemotherapy has low efficacy and poor long-term prognosis for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
- Conditions
- Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
- Trial name
- NCT06581081
- Testing
- Senl_B19 autologous CAR-T (S1904) treatment
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Peking University People's Hospital
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant
This phase I trial studies the effects and safety of adding azacitidine (5-AzaC) to the standard of care (Soc) for patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after being treated with…
- Trial name
- NCT01390311
- Testing
- Azacitidine, Pre-DLI Salvage Chemotherapy, Donor Leukocyte Infusion (DLI)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Metastatic Cancer
Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung
RATIONALE: Biological therapy, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00301730
- Testing
- aldesleukin, therapeutic tumor infiltrating lymphocytes, trastuzumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic Organs; Disorder
Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Primary Objective: 1. To evaluate the safety of orally administered Lactobacillus plantarum strains 299 and 299v, a probiotic, in patients undergoing allogeneic myeloablative HSCT, as measured by incidence of Lactobacillus…
- Trial name
- NCT01010867
- Testing
- Lactobacillus plantarum strains 299 and 299v
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Columbia University
The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
Ruxolitinib as GVHD Prophylaxis in AA Patients
Our study aimed to determine the prophylactic value of ruxolitinib for aGVHD in HSCT recipients of AA.Ruxolitinib was initiated at the beginning of conditioning regimen at 5 twice daily until 3 months post-transplantation.
- Trial name
- NCT05914714
- Testing
- Ruxolitinib 5 MG BID Oral Tablet
- Volunteers
- 46 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
This is a multi-institution, non-randomized, open label, Phase IIa prospective trial to evaluate the safety and tolerability of maintenance lenalidomide after allogeneic hematopoietic stem cell transplantation (HCT).
- Trial name
- 07-REV (NCT00847639)
- Testing
- lenalidomide
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Experimental
hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure
The broad, long-term goal of this proposal is to improve the results and applicability of islet allotransplantation early in the course of type 1 diabetes through the administration of selective and short-term immunotherapy.
- Conditions
- Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Experimental, Transplantation, Homologous, Islets of Langerhans Transplantation
- Trial name
- NCT00008801
- Testing
- hOKT3gamma1 (Ala-ala)
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)